Full Breakdown
Eli Lilly’s Q3 2026 Earnings Surge and Outlook Expansion
By Drooid · · How we work
In this breakdown
01
Core Results and Guidance Update
Eli Lilly reported third-quarter 2026 revenue of $24.4 billion, a 39% year-over-year increase. Adjusted earnings per share were $7.48, beating the $6.26 consensus. The company lifted full-year 2026 revenue guidance to $91-$92 billion (from $85-$87 billion) and non-GAAP earnings outlook to $35-$36 per share. Shares rose about 4% in early trading.
02
Background & Context
Growth is driven by the GLP-1 portfolio. Weight-loss drugs Zepbound and Mounjaro have sustained strong sales, while Medicare’s “Bridge” pilot, launched in July, now covers GLP-1s for weight loss, adding roughly 500,000 beneficiaries and directing about 70% of new patients to Lilly’s products. The oral obesity pill Foundayo, launched in April, has lagged forecasts.
Visual evidence
Images from the story
03
Data & Statistics
- Mounjaro: worldwide revenue $10.72 billion (up 65% YoY); U.S. sales about $5 billion.
- Zepbound: Q3 revenue $5.35 billion, a 49% increase YoY.
- Foundayo: Q3 sales $184 million, below the $229 million forecast.
- U.S. obesity-diabetes market share: 63% for Lilly vs. 36.6% for Novo Nordisk; internationally 58.4% vs. 41.6%.
- U.S. revenue rose 34% to $15.1 billion; overall volume up 41% while realized prices fell 7%.
- A $410 million milestone payout was made for Jardiance under Lilly’s partnership with Boehringer Ingelheim.
- Net income was $6.45 billion (reported EPS $7.22); non-GAAP net income $6.68 billion.
04
Official Statements & Responses
Lilly’s earnings release highlighted “strong momentum” and the Bridge program’s role in expanding patient access. About 500,000 Medicare patients are using its GLP-1 drugs through the program, with roughly seven-in-ten new participants choosing Lilly’s offerings. JPMorgan analyst Chris Schott called the results “strong momentum.” Chris Klomp, HHS Chief Counselor, noted 1.1 million patients enrolled in the Medicare Bridge program as of early October.
05
What It Means for the Market
The beat and upgraded guidance reinforce Lilly’s position as the world’s most valuable drugmaker and give it capacity to pursue new therapeutic areas. Dominant market share and expanding insurance coverage create a barrier for rivals, though slower uptake of Foundayo and pricing pressures highlight the need for continued pipeline innovation.
06
Upcoming Developments
- Retatrutide, an experimental obesity drug, is slated for a regulatory submission in early 2027.
- Lilly completed its acquisition of Merida Biosciences and finalized the purchase of AtaiBeckley, expanding its autoimmune-allergy pipeline.
- New manufacturing facilities are under construction in Richmond, Virginia, and Houston, Texas.
- Phase 3 trials for EloraTZP begin in Q4 2026, and positive Phase 3 results for retatrutide versus Ozempic 2 mg have been reported.
07
Conflicting Reports & Gaps
All sources present consistent figures for revenue, earnings, and market share; no substantive discrepancies were identified. The primary gap is limited insight into the long-term pricing trajectory for GLP-1 drugs under evolving Medicare coverage policies.